LBO-06-Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients
Journal article published in 2019 by
This paper was not found in any repository, but could be made available legally by the author.
Preprint: archiving allowed
Data provided by